Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:50929 |
Name | mucosal melanoma |
Definition | A melanoma that has_material_basis_in melanocytes located_in mucosal membranes lining the respiratory, gastrointestinal and urogenital tract. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer cell type cancer melanoma mucosal melanoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
KIT C443S | Imatinib | mucosal melanoma | sensitive | detail... |
BRAF V600L | Dabrafenib + Trametinib | mucosal melanoma | predicted - sensitive | detail... |
KIT N822K | Avapritinib | mucosal melanoma | predicted - sensitive | detail... |
KIT exon17 | Avapritinib | mucosal melanoma | predicted - sensitive | detail... |
EML4 - ALK | Crizotinib | mucosal melanoma | sensitive | detail... |
EML4 - ALK | Ceritinib | mucosal melanoma | sensitive | detail... |
EML4 - ALK | Entrectinib | mucosal melanoma | sensitive | detail... |
EML4 - ALK | ASP3026 | mucosal melanoma | sensitive | detail... |
EML4 - ALK | Alectinib | mucosal melanoma | sensitive | detail... |
NRAS Q61H | Trametinib | mucosal melanoma | sensitive | detail... |
NRAS Q61L | Belvarafenib | mucosal melanoma | predicted - sensitive | detail... |
BRAF D594G | Belvarafenib | mucosal melanoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02645149 | Phase II | Trametinib Pazopanib Ceritinib Ribociclib + Trametinib | Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma (MatchMel) | Recruiting | AUS | 0 |
NCT02748564 | Phase II | Aldesleukin + Pembrolizumab | Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma | Terminated | USA | 0 |
NCT02818023 | Phase I | Cobimetinib + Pembrolizumab + Vemurafenib | Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma | Terminated | USA | 0 |
NCT02879162 | Phase II | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours | Unknown status | CAN | 0 |
NCT02978443 | Phase II | Ipilimumab + Nivolumab | A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab | Terminated | USA | 0 |
NCT03220009 | Phase II | Ipilimumab + Nivolumab | Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma | Withdrawn | USA | 0 |
NCT03235245 | Phase II | Binimetinib + Encorafenib Ipilimumab + Nivolumab | Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib (EBIN) | Active, not recruiting | POL | NLD | ITA | GBR | FRA | FIN | ESP | DNK | DEU | 0 |
NCT03241186 | Phase II | Ipilimumab + Nivolumab | Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma | Active, not recruiting | USA | 0 |
NCT03313206 | Phase II | Pembrolizumab | Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma (IMMUQ) | Recruiting | FRA | 0 |
NCT03340129 | Phase II | Ipilimumab + Nivolumab | Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) (ABC-X) | Recruiting | NOR | AUS | 0 |
NCT03817125 | Phase I | Nivolumab + SER-401 Vancomycin Nivolumab | Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention (MCGRAW) | Completed | USA | 0 |
NCT03875079 | Phase I | Pembrolizumab + RO6874281 | A Phase IB Study To Evaluate Safety And Therapeutic Activity Of RO6874281, An Immunocytokine, Consisting Of Interleukin-2 Variant Targeting Fibroblast Activation Protein-A, In Combination With Pembrolizumab (Anti-Pd-1), In Participants With Previously Untreated Advanced And/Or Metastatic Melanoma | Completed | USA | FRA | ESP | CAN | BEL | AUS | 1 |
NCT03991741 | Phase I | Aldesleukin | Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors | Recruiting | USA | 0 |
NCT04042506 | Phase II | Nivolumab | SBRT as a Vaccination for Metastatic Melanoma | Withdrawn | USA | 0 |
NCT04139902 | Phase II | Cobolimab + Dostarlimab-gxly Dostarlimab-gxly | PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor TSR-022 and PD-1 Inhibitor Dostarlimab (TSR-042) | Recruiting | USA | 0 |
NCT04250597 | Phase I | GNX102 | Study of GNX102 in Patients With Advanced Solid Tumors | Terminated | USA | 1 |
NCT04318717 | Phase Ib/II | Pembrolizumab | Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma | Recruiting | USA | 0 |
NCT04493203 | Phase II | Axitinib + Nivolumab | Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma | Active, not recruiting | USA | 0 |
NCT04551352 | Phase I | RO7293583 + Tocilizumab Obinutuzumab + RO7293583 + Tocilizumab | A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas | Completed | USA | ESP | DNK | CAN | BEL | AUS | 0 |
NCT04570332 | Phase II | BO-112 + Pembrolizumab | BO-112 With Pembrolizumab in Unresectable Malignant Melanoma (SPOTLIGHT203) | Active, not recruiting | FRA | ESP | 0 |
NCT04577807 | Phase II | PVSRIPO + unspecified PD-1 antibody PVSRIPO | PVSRIPO With or Without Immune Checkpoint Blockade in Patients With Advanced PD-1 Refractory Melanoma | Active, not recruiting | USA | 0 |
NCT04592653 | Phase Ib/II | ALKS 4230 ALKS 4230 + Pembrolizumab | Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) (ARTISTRY-3) | Active, not recruiting | USA | ESP | 0 |
NCT04830124 | Phase II | ALKS 4230 | Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6 (ARTISTRY-6) | Recruiting | USA | ITA | GBR | ESP | CAN | AUS | 2 |
NCT04987996 | Phase II | Pembrolizumab Belapectin + Pembrolizumab | GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients | Withdrawn | USA | 0 |
NCT05061134 | Phase II | Ceralasertib + Durvalumab Ceralasertib | A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition (MONETTE) | Active, not recruiting | USA | POL | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 1 |
NCT05086692 | Phase Ib/II | MDNA11 + Pembrolizumab | A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1) | Recruiting | USA | CAN | AUS | 1 |
NCT05089370 | Phase Ib/II | Decitabine and Cedazuridine + Nivolumab | Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma | Recruiting | USA | 0 |
NCT05098210 | Phase I | NeoVax + Nivolumab + Poly ICLC | Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer | Recruiting | USA | 0 |
NCT05111574 | Phase II | Nivolumab Cabozantinib + Nivolumab | Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery | Recruiting | USA | CAN | 0 |
NCT05384496 | Phase II | Axitinib + Ipilimumab + Nivolumab Axitinib + Nivolumab | Axitinib and Nivolumab for the Treatment of Mucosal Melanoma | Recruiting | USA | 0 |
NCT05415072 | Phase Ib/II | DYP688 | A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas | Recruiting | USA | NLD | FRA | ESP | DEU | CHE | AUS | 0 |
NCT05428007 | Phase II | Ipilimumab + Nivolumab and relatlimab-rmbw + Sarilumab | Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma | Recruiting | USA | 0 |
NCT05482074 | Phase II | Olaparib | Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 | Withdrawn | 0 | |
NCT05545969 | Phase II | Lenvatinib + Pembrolizumab | Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma (Neo PeLeMM) | Withdrawn | AUS | 0 |
NCT05628883 | Phase I | Cyclophosphamide + Fludarabine TBio-4101 Aldesleukin | Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma | Recruiting | USA | 0 |
NCT05913388 | Phase II | Pembrolizumab GB1211 + Pembrolizumab | GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma | Recruiting | USA | 0 |
NCT06319196 | Phase II | Nivolumab Nivolumab and relatlimab-rmbw | Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma (ClearMe) | Recruiting | CAN | 0 |
NCT06594991 | Phase II | Cemiplimab + Fianlimab + Ipilimumab | A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma | Recruiting | USA | 0 |
NCT06598371 | Phase Ib/II | Cyclophosphamide + Fludarabine Aldesleukin + KSQ-004EX KSQ-004EX | A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors | Not yet recruiting | USA | 0 |
NCT06651151 | Phase II | LTX-315 + Pembrolizumab | NeoLIPA: Neoadjuvant LTX-315 in Combination With Pembrolizumab in Resectable Stage III/IV Melanoma (NeoLIPA) | Recruiting | NOR | 0 |